摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[2-(methylsulfonyl)ethyl]benzenesulfonyl chloride | 347146-82-1

中文名称
——
中文别名
——
英文名称
4-[2-(methylsulfonyl)ethyl]benzenesulfonyl chloride
英文别名
4-(2-Methylsulfonylethyl)benzenesulfonyl chloride
4-[2-(methylsulfonyl)ethyl]benzenesulfonyl chloride化学式
CAS
347146-82-1
化学式
C9H11ClO4S2
mdl
——
分子量
282.769
InChiKey
DPONYUBCYIPSQH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    16
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    85
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    4-[2-(methylsulfonyl)ethyl]benzenesulfonyl chloride 生成 N-(8-Bromoquinoline-3-yl)-4-(2-methylsulfonylethyl)benzenesulfonamide
    参考文献:
    名称:
    Integrin expression inhibitors
    摘要:
    本发明提供了一种整合素表达抑制剂,以及基于整合素抑制作用的用于治疗动脉硬化、银屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的药剂、抗凝剂或癌症转移抑制剂。即提供了一种包含以下式(I)所表示的磺胺化合物、其药理学上可接受的盐或其水合物作为活性成分的整合素表达抑制剂。 在该式中,B表示一个C6-C10芳基环或6-至10成员杂芳基环,可能具有取代基,并且环的一部分可能是饱和的;K表示一个单键,-CH═CH-或-(CR 4b R 5b ) m b -(其中R 4b 和R 5b 相同或不同,各自表示氢原子或C1-C4烷基;m b 表示1或2的整数);R 1 表示氢原子或C1-C6烷基;Z表示一个单键或-CO-NH-;R表示一个C6-C10芳基环或6-至10成员杂芳基环,可能具有取代基,并且环的一部分可能是饱和的,分别。
    公开号:
    US20040018192A1
点击查看最新优质反应信息

文献信息

  • Sulfonamide-containing heterocyclic compounds
    申请人:——
    公开号:US20030144507A1
    公开(公告)日:2003-07-31
    The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. 1 In the formula, A is hydrogen atom, a halogen atom, a C1-C4 alkyl or alkoxy group which may be substituted with a halogen atom, or cyano group; B is an optionally substituted aryl group or monocyclic heteroaryl group, or: 2 (wherein, the ring Q is an aromatic ring which may have nitrogen atom; and the ring M is a ring sharing a double bond with the ring Q, which ring may have a heteroatom; and the rings Q and M may share nitrogen atom); K is a single bond; T, W, X and Y are the same as or different from each other and each is ═C(D)— (wherein, D is hydrogen or a halogen atom) or nitrogen atom; U and V are the same as or different from each other and each is ═C(D)—, nitrogen atom, —CH 2 —, oxygen atom or —CO—; Z is a single bond or —CO—NH—; and R 1 is hydrogen atom, etc.
    本发明提供了含有磺胺基或磺酰基脲的杂环化合物。具体而言,提供了由式(I)表示的杂环化合物,其药学上可接受的盐或其水合物。 在该式中,A为氢原子、卤原子、可能被卤原子取代的C1-C4烷基或烷氧基,或氰基;B为可选择取代的芳基或单环杂芳基,或: (其中,环Q为可能含有氮原子的芳环;环M为与环Q共享双键的环,该环可能含有杂原子;环Q和环M可能共享氮原子);K为单键;T、W、X和Y彼此相同或不同,每个都是═C(D)—(其中,D为氢或卤原子)或氮原子;U和V彼此相同或不同,每个都是═C(D)—、氮原子、—CH 2 —、氧原子或—CO—;Z为单键或—CO—NH—;R 1 为氢原子,等等。
  • Integrin expression inhibitor
    申请人:Wakabayashi Toshiaki
    公开号:US20050176712A1
    公开(公告)日:2005-08-11
    The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
    本发明提供了一种整合素表达抑制剂,并提供了一种基于整合素抑制作用的用于治疗动脉硬化、银屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病的药剂、抗凝剂或癌症转移抑制剂。换句话说,本发明提供了一种整合素表达抑制剂,其包括以下式(I)所表示的磺酰胺化合物作为活性成分、其药学上可接受的盐或其水合物: 其中,在上述式中,B表示C6-C10芳基环或6-至10元杂环芳基环,其中可能有取代基,并且环的一部分可能是饱和的;K表示单键,-CH═CH-或-(CR4bR5b)mb-(其中R4b和R5b相同或不同,每个表示氢原子或C1-C4烷基;mb表示1或2的整数);R1表示氢原子或C1-C6烷基;Z表示单键或-CO-NH-;R分别表示C6-C10芳基环或6-至10元杂环芳基环,其中可能有取代基,并且环的一部分可能是饱和的。
  • INTEGRIN EXPRESSION INHIBITOR
    申请人:WAKABAYASHI Toshiaki
    公开号:US20100267754A1
    公开(公告)日:2010-10-21
    The present invention provides an integrin expression inhibitor, and an agent for treating arterial sclerosis, psoriasis, cancer, retinal angiogenesis, diabetic retinopathy or inflammatory diseases, an anticoagulant, or a cancer metastasis suppressor on the basis of an integrin inhibitory action. Namely, it provides an integrin expression inhibitor comprising, as an active ingredient, a sulfonamide compound represented by the following formula (I), a pharmacologically acceptable salt thereof or a hydrate of them, wherein in the formula, B means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated; K means a single bond, —CH═CH— or —(CR 4b R 5b ) m b — (wherein R 4b and R 5b are the same as or different from each other and each means hydrogen atom or a C1-C4 alkyl group; and m b means an integer of 1 or 2); R 1 means hydrogen atom or a C1-C6 alkyl group; Z means a single bond or —CO—NH—; and R means a C6-C10 aryl ring or 6- to 10-membered heteroaryl ring which may have a substituent and in which a part of the ring may be saturated, respectively.
    本发明提供了一种整合素表达抑制剂,以及一种用于治疗动脉硬化、银屑病、癌症、视网膜血管生成、糖尿病视网膜病变或炎症性疾病、抗凝剂或癌症转移抑制剂的药剂,其基于整合素抑制作用。即,提供一种整合素表达抑制剂,其包括以下式(I)所表示的磺酰胺化合物作为活性成分,其药理学上可接受的盐或水合物,其中在该式中,B表示一个C6-C10芳基环或6-到10成员杂环环,可以有取代基,在环中的一部分可能是饱和的;K表示单键,—CH═CH—或—(CR4bR5b)mb—(其中R4b和R5b相同或不同,每个表示氢原子或C1-C4烷基;mb表示1或2的整数);R1表示氢原子或C1-C6烷基;Z表示单键或—CO—NH—;R分别表示C6-C10芳基环或6-到10成员杂环环,可以有取代基,在环中的一部分可能是饱和的。
  • BICYCLIC HETEROCYCLIC SULFONAMIDE AND SULFONIC ESTER DERIVATIVES
    申请人:Eisai Co., Ltd.
    公开号:EP0673937A1
    公开(公告)日:1995-09-27
    Novel bicyclic heterocyclic sulfonamide and sulfonic ester derivatives represented by general formula (I) having an antitumor activity and a reduced toxicity, pharmacologically acceptable salts thereof, and a process for producing the same; wherein ring A represents an optionally substituted mono- or bicyclic aromatic group; ring B represents an optionally substituted 6-membered unsaturated hydrocarbon ring or 6-membered unsaturated heterocyclic group containing one nitrogen atom; ring C represents an optionally substituted 5-membered heterocyclic group containing one or two nitrogen atoms; W represents a single bond or -CH=CH-; X represents -NR¹- or oxygen; Y represents carbon or nitrogen; Z represents -NR²- or nitrogen; and R¹ and R² represent each independently hydrogen or lower alkyl.
    由通式(I)代表的具有抗肿瘤活性且毒性降低的新型双环杂环磺酰胺和磺酸酯衍生物、其药理学上可接受的盐,以及生产该衍生物的工艺;其中环A代表任选取代的单环或双环芳香基团,环B代表任选取代的6元不饱和烃环或含有一个氮原子的6元不饱和杂环基团;环C代表任选取代的5元杂环基团;环 B 代表任选取代的含一个氮原子的 6 元不饱和烃环或 6 元不饱和杂环基团; 环 C 代表任选取代的含一个或两个氮原子的 5 元杂环基团; W 代表单键或-CH=CH-; X 代表-NR¹-或氧; Y 代表碳或氮; Z 代表-NR²-或氮;以及 R¹ 和 R² 各自独立地代表氢或低级烷基。
  • HETEROCYCLIC COMPOUNDS HAVING SULFONAMIDE GROUPS
    申请人:Eisai Co., Ltd.
    公开号:EP1243583A1
    公开(公告)日:2002-09-25
    The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them. In the formula, A is hydrogen atom, a halogen atom, a C1-C4 alkyl or alkoxy group which may be substituted with a halogen atom, or cyano group; B is an optionally substituted aryl group or monocyclic heteroaryl group, or: (wherein, the ring Q is an aromatic ring which may have nitrogen atom; and the ring M is a ring sharing a double bond with the ring Q, which ring may have a heteroatom; and the rings Q and M may share nitrogen atom); K is a single bond; T, W, X and Y are the same as or different from each other and each is =C(D)- (wherein, D is hydrogen or a halogen atom) or nitrogen atom; U and V are the same as or different from each other and each is =C(D)-, nitrogen atom, -CH2-, oxygen atom or -CO-; Z is a single bond or -CO-NH-; and R1 is hydrogen atom, etc.
    本发明提供了一种含磺酰胺或磺酰脲的杂环化合物。具体地说,它提供了一种由式(I)代表的杂环化合物、其药理学上可接受的盐或它们的水合物。 式中,A为氢原子、卤素原子、可被卤素原子或氰基取代的C1-C4烷基或烷氧基;B为任选取代的芳基或单环杂芳基,或: (其中,环 Q 是芳香环,可带有氮原子;环 M 是与环 Q 共用双键的环,该环可带有杂原子;环 Q 和环 M 可共用氮原子);K 是单键;T、W、X 和 Y 彼此相同或不同,且各自为 =C(D)-(其中,D 为氢原子或卤素原子)或氮原子;U 和 V 彼此相同或不同,且各自为 =C(D)-、氮原子、-CH2-、氧原子或 -CO-;Z 为单键或 -CO-NH-;R1 为氢原子等。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐